Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 17/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809898 | 0.89 | EGFR (0.66) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL4477751 | 0.87 | EGFR (0.66) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL4476040 | 0.85 | ERBB2 (0.79) | EGFRERBB2KCNH2 | |
| SCHEMBL3813145 | 0.84 | EGFR (0.65) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL4483295 | 0.84 | ERBB2 (0.67) | EGFRERBB2KCNH2 | |
| SCHEMBL4469476 | 0.83 | ERBB2 (0.78) | EGFRERBB2KCNH2 | |
| SCHEMBL3811397 | 0.81 | ERBB2 (0.75) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL4479825 | 0.81 | EGFR (0.58) | EGFRERBB2KCNH2 | |
| SCHEMBL4483812 | 0.81 | EGFR (0.58) | EGFRERBB2KCNH2 | |
| SCHEMBL4027906 | 0.80 | EGFR (1.00) | EGFRERBB2FLT1EPHA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101787019-A | Quinazoline derivant | ASTRAZENECA AB | 2010-07-28 | — | — | CN | disclosed |
| US-7625908-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20070244136-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| CN-1906178-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
| EP-1685116-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005051923-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244136-A1 | Quinazoline Derivatives | ERBB2, ABL1, MKI67 | EGFR 10/4885ERBB2 1/4885FLT1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.